Syncona Limited

Publication of 2023 Annual Report and Notice of Annual General Meeting

28 June 2023

Syncona Ltd, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, today announces that it has published its Annual Report and Accounts for the year ended 31 March 2023 ("2023 Annual Report") and its Notice of the Annual General Meeting 2023.

In compliance with Listing Rule 9.6.1, these documents will today be filed with the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

The Notice of the Annual General Meeting 2023 is available on Syncona's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/. The 2023 Annual Report is available on Syncona's website at https://www.synconaltd.com/investors/results-and-presentations/. Printed copies of these documents are also being posted to shareholders where requested.

Syncona's Annual General Meeting will be held at 10:30am on 1 August 2023 at the offices of Citco Fund Services (Guernsey) Limited, Frances House, Sir William Place, St. Peter Port, Guernsey, GY1 1GX. Shareholders are encouraged to ensure that their votes are counted at the 2023 Annual General Meeting by appointing the chair of the 2023 Annual General Meeting as their proxy in line with the procedures set out in the Notice of Annual General Meeting.

Enquiries

Syncona Limited
Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.